Supraventricular ArrhythmiasNCT07291544
Management of Supraventricular Tachycardias in Children
An observational study of Supraventricular Arrhythmias and Children, run by Paris Cardiovascular Research Center (Inserm U970).
Trial summary
Background Supraventricular tachycardias (SVTs) are the most common arrhythmic events in children, with an estimated incidence of 13 per 100,000 per year before the age of 18. Few large patient cohorts have been reported, as most published studies are single-center. Read more about this study
- Who is it for?
- Ages 0 to 18 years
- Conditions the study is for
- Supraventricular Arrhythmias, Children, Management
- What is being tested?
- Management of children with supraventricular tachycardias
- How many people
- 1,400 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2000to 30 Sep 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: All children <18 years old with a documented episode (ECG, Holter-ECG, wearable device, or implantable device) of sustained SVT (>30 seconds) will be eligible. Although most children in this context do not have structural heart disease, those with congenital or structural heart disease will also be eligible. Participation will be proposed to all pediatric cardiology centers in France through the Filiale de Cardiologie Pédiatrique et Congénitale (FCPC).
Who may be able to join
- Age <18 years at the time of the first documented supraventricular tachycardia episode
Who cannot join
- Early postoperative supraventricular tachycardia (<30 days)
- Age ≥18 years at the first documented supraventricular tachycardia episode
- Fetal tachycardias without postnatal recurrence
- Atrial extrasystoles without sustained runs (<30 seconds)
About this study
Official title: Management of Supraventricular Tachycardias in Children: A National Multicenter Study
Background
Supraventricular tachycardias (SVTs) are the most common arrhythmic events in children, with an estimated incidence of 13 per 100,000 per year before the age of 18. Few large patient cohorts have been reported, as most published studies are single-center. Large-scale studies come from medico-administrative databases, which lack the granularity needed for detailed analysis of outcomes according to the therapies used and the type of SVT.
Read more
Furthermore, although a large proportion of neonatal SVTs do not recur (spontaneous resolution of the accessory pathway), there are limited comparative data on the effectiveness of antiarrhythmic therapies specifically in children after the age of 1 year. Management therefore varies greatly, in part because current guidelines propose different therapeutic options based on low-level evidence.
Objectives:
- Describe the management of SVTs (antiarrhythmic therapies and catheter ablation) in children in France
- Compare the effectiveness of different antiarrhythmic treatments according to age (<1 year and >1 year) and type of SVT
- Analyze the incidence of adverse events and complications associated with antiarrhythmic treatments and catheter ablation
- Conditions
- Supraventricular Arrhythmias, Children, Management
- Being tested
- Management of children with supraventricular tachycardias
- Keywords
- supraventricular arrhythmias, supraventricular tachycardia, children
- Medical subject headings
- Tachycardia, Supraventricular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Management of children with supraventricular tachycardiasOther
Observational analysis of the management of supraventricular tachycardias (antiarrhythmic drugs and catheter ablations)
What is being measured
The primary outcome is the main question the study is designed to answer.
Antiarrhythmic therapies
Proportion of antiarrhythmic therapies used by age group (<1 year and >1 year)
Measured: At the time of the first supraventricular tachycardia recorded
Catheter ablation
Proportion of children referred for catheter ablation and age at ablation
Measured: At the time of first episode of supraventricular tachycardia or after recurrence
Recurrence of supraventricular tachycardia
Time between antiarrhythmic therapy initiation and first recurrence, according to treatment and age
Measured: At 1 year after antiarrhythmic drug initiation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Dec 2025
- Study start1 Jan 2000
- Primary completion30 Sep 2025
- Study completion30 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Supraventricular ArrhythmiasStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1,400 participants (actual)
Sponsor and investigators
- Lead sponsor
- Paris Cardiovascular Research Center (Inserm U970)
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Victor WALDMANN, Paris Cardiovascular Research Center (Inserm U970)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07291544
- Sponsor's protocol ID
- WALDMANN202501
- Status last verified
- Dec 2025
- First submitted
- 5 Dec 2025
- Last updated
- 2 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Management of Supraventricular Tachycardias in Children: A National Multicenter Study
- ClinicalTrials.gov ID
- NCT07291544
- Acronym / sponsor ID
- WALDMANN202501
- Conditions
- Supraventricular Arrhythmias, Children, Management
- Keywords
- supraventricular arrhythmias, supraventricular tachycardia, children
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,400 participants (actual)
- Lead sponsor
- Paris Cardiovascular Research Center (Inserm U970)Other government
- Study start
- 1 Jan 2000 (actual)
- Primary completion
- 30 Sep 2025 (actual)
- Study completion
- 30 Sep 2025 (actual)
- First posted
- 18 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background
Supraventricular tachycardias (SVTs) are the most common arrhythmic events in children, with an estimated incidence of 13 per 100,000 per year before the age of 18. Few large patient cohorts have been reported, as most published studies are single-center. Large-scale studies come from medico-administrative databases, which lack the granularity needed for detailed analysis of outcomes according to the therapies used and the type of SVT.
Furthermore, although a large proportion of neonatal SVTs do not recur (spontaneous resolution of the accessory pathway), there are limited comparative data on the effectiveness of antiarrhythmic therapies specifically in children after the age of 1 year. Management therefore varies greatly, in part because current guidelines propose different therapeutic options based on low-level evidence.
Objectives:
- Describe the management of SVTs (antiarrhythmic therapies and catheter ablation) in children in France
- Compare the effectiveness of different antiarrhythmic treatments according to age (<1 year and >1 year) and type of SVT
- Analyze the incidence of adverse events and complications associated with antiarrhythmic treatments and catheter ablation
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 0 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- All children <18 years old with a documented episode (ECG, Holter-ECG, wearable device, or implantable device) of sustained SVT (>30 seconds) will be eligible. Although most children in this context do not have structural heart disease, those with congenital or structural heart disease will also be eligible. Participation will be proposed to all pediatric cardiology centers in France through the Filiale de Cardiologie Pédiatrique et Congénitale (FCPC).
Key inclusion criteria (1 listed)
- Age <18 years at the time of the first documented supraventricular tachycardia episode
Key exclusion criteria (4 listed)
- Early postoperative supraventricular tachycardia (<30 days)
- Age ≥18 years at the first documented supraventricular tachycardia episode
- Fetal tachycardias without postnatal recurrence
- Atrial extrasystoles without sustained runs (<30 seconds)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Management of children with supraventricular tachycardiasObservational analysis of the management of supraventricular tachycardias (antiarrhythmic drugs and catheter ablations) | Other | – |
Primary outcome
Antiarrhythmic therapies
Time frame: At the time of the first supraventricular tachycardia recorded
Proportion of antiarrhythmic therapies used by age group (<1 year and >1 year)
Catheter ablation
Time frame: At the time of first episode of supraventricular tachycardia or after recurrence
Proportion of children referred for catheter ablation and age at ablation
Recurrence of supraventricular tachycardia
Time frame: At 1 year after antiarrhythmic drug initiation
Time between antiarrhythmic therapy initiation and first recurrence, according to treatment and age
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Supraventricular Arrhythmias
RecruitingObservational study
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Arrhythmia, Bradycardia
RecruitingObservational study
AI-Based Differential Diagnosis and Localization of Tachycardia Using ECG: Multicenter Registry (EP-AI ASSIST)
Tachycardia, Paroxysmal Supraventricular Tachycardia
Not yet recruiting
Head-to-Head (H2H) Comparison of Ambulatory Cardiac ECG Monitors in Japan
Atrial Fibrillation (AF), Atrial Flutter
Active, not recruitingPhase 1/2
Treatment of Orthostatic Intolerance
Tachycardia, Chronic Orthostatic Intolerance
Not yet recruitingObservational study
Cardiac Arrhythmias in Pediatric Emergency Department
Arrhythmias, Cardiac, Tachycardia, Supraventricular
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Supraventricular Arrhythmias and Children, run by Paris Cardiovascular Research Center (Inserm U970).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Antiarrhythmic therapies (time frame: At the time of the first supraventricular tachycardia recorded). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jan 2026.